Robert Preti, PhD, Opens the 2017 Cell & Gene Meeting on the Mesa
PCT Team | November 2, 2017
At this year's Cell & Gene Meeting on the Mesa, Robert Preti, PhD, Chairman of the Alliance for Regenerative Medicine and President and CEO of Hitachi Chemical Advanced Therapeutics Solutions, LLC, opened the conference with a state of the industry oveview. In his welcoming remarks, Dr. Preti discusses a robust and expanding global sector with over 800 therapeutic developers now worldwide, alongside a 24% year over year growth in on-going clincal trials.
To hear the full industry update as from the Meeting on the Mesa 2017 kick-off, watch the video here:
At the 2017 Meeting on the Mesa, there were over 970 attendees over the course of the 3 day conference with over 70 presentations and interactive panels. Dr. Preti moderated an expert panel to explore a number of questions including:
What are the benefits to going global in terms of cell therapy development and commercialization strategies?
How are developers establishing strategies and capacity for global development and manufacturing?
What considerations go into the choice to expand geographic reach for a product candidate? Can global strategy wait until the first commercial approval is achieved? What is the optimum timing?
What are the pitfalls or challenges of a global strategy and how can they be avoided?
Watch the full workshop, Helping Your Cell Therapy Go Global, to hear the panelists answers to those questions:
For more information on helping your cell therapy go global, visit our Resource Center.
PCT TeamOur leaders have worked on some of the major cell therapies of the past 10 years, and have extensive experience in pharmaceutical-grade quality and operations.
Subscribe to our blog for instant updates on challenges and trends in cell therapy development, manufacturing and commercialization.